GCLC and cancer: Other publications identified the antioxidant glutathione (GSH), the glutamate-cysteine ligase synthetase catalytic subunit (GCLC), a rate-limiting enzyme for GSH synthesis, and EZH2, a histone-lysine N-methyltransferase enzyme that participates in histone methylation and transcriptional repression, as novel treatment options for cancers involving ARID1A mutations [46, 47].